AMLN

Recent Articles

Banking on Buyouts in Biotech: Is It Smart?

Unless you really understand medicine, it's a very risky game. The chances of a little company scoring big and getting bought out are usually slim. More 

9 Biotech Buyout Players to Watch

The deal between Human Genome Sciences and GlaxoSmithKline is just the most recent of big pharma buyouts -- and these biotech players could be next. More 

M&A: Where the Hotspots Are

Both the number of deals and their value are down, but there's strong signs of life if you know where to look. Here's a guide to where the action is. More 

Manufacturing Woes Stop the Mo: Monday’s IP Market Recap

Markets reacted to a disappointing manufacturing report, starting out in negative territory before coming back for slight gains in the S&P and Nasdaq. More 

Should I Buy Bristol-Myers Squibb? 3 Pros, 3 Cons

Its deal to buy diabetes-drug maker Amylin will help, given that market's potential. Still, patent expirations loom large and won't be easily overcome. More 

Bristol-Myers Squibb to Buy Amylin for $7B

Bristol-Myers Squibb announced plans to purchase Amylin Pharmaceuticals for $7 billion on Friday and will market its drugs with AztraZeneca. More 

Cue the Biotech M&A Attack!

A rush of buyout activity in biotechs like Human Genome and Illumina could produce more frenzied M&A deals down the road. More